This month, the Food and Drug Administration approved a new treatment for Alzheimer's disease -- the first in nearly 20 years. But the decision was not without controversy, with doctors split on how they feel about the treatment.

Since the approval, doctors have สล็อต ฝาก-ถอน true wallet faced questions from patients and families desperate for good news, but they are conflicted on whether to recommend and prescribe the new drug, developed by Biogen.

“The news is out, and patients and families are calling with their hopes up,” said Dr. Ipsit Vahia, a geriatric psychiatrist and researcher and the medical director of the Geriatric Psychiatry Outpatient Services at McLean Hospital.

"I think many people, including myself, find themselves conflicted between a strong urge to do something to help, using a tool that we couldn't just offer previously, and balancing of course, first doing no harm and also not knowing for sure that [it] works for everyone,” Vahia said.

“So if you ask, would I recommend [Aduhelm]? It's complicated."

The FDA granted a broad approval for Aduhelm, the so-called "drug label" open to any patient with Alzheimer's disease. But the clinical trials studying the drug only looked at a narrow group of patients: those recently diagnosed and those early in the progression of their disease.

In the resulting uncertainty, neurologists, psychiatrists and hospital systems are coming together to establish guidelines on how to safely prescribe the drug.

“The bar to get the medication is still very high, and appropriately so,” said Dr. Brent Forester, a geriatric psychiatrist and chief of the Center of Excellence in Geriatric Psychiatry at McLean Hospital. “Despite the FDA label, I would limit using. Aduhelm to only the patients within the study population, in addition to all exclusion criteria within the trial."